JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic steatohepatitis
Epistemonikos ID: 55477ff995fe54bd4cd4c3b5546373e560c930d2
First added on: May 12, 2024